Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 01, 2015 6:40 AM ET

Biotechnology

Company Overview of GlobeImmune Inc.

Company Overview

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and has completed Phase 2a clinical trial to treat non-small cell lung cancer, as well as in Phase 2a clinical study for the treatment of colorectal cancer. The company’s product candidates also comprise GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer; GI-6301, which is in Phase 1 clinical trial for the treatment of chordoma and breast cancer; and GS-4774 that is in Phase 2 clin...

1450 Infinite Drive

Louisville, CO 80027

United States

Founded in 1995

22 Employees

Phone:

303-625-2700

Fax:

303-625-2710

Key Executives for GlobeImmune Inc.

Chief Executive Officer, President and Director
Age: 64
Total Annual Compensation: $388.1K
Vice President of Finance, Treasurer and Secretary
Age: 50
Total Annual Compensation: $191.5K
Vice President of Corporate Development
Age: 46
Total Annual Compensation: $191.5K
Compensation as of Fiscal Year 2014.

GlobeImmune Inc. Key Developments

Kirk Christoffersen to Leave GlobeImmune Inc. as Vice President, Corporate Development, Effective Aug. 3, 2015

On July 16, 2015 GlobeImmune Inc. announced that Kirk Christoffersen would be leaving the company effective as of August 3, 2015. Mr. Christoffersen is currently the company's Vice President, Corporate Development.

GlobeImmune Inc. Ratifies the Appointment of EKS&H LLLP as Independent Registered Public Accounting Firm

GlobeImmune Inc. announced that at AGM held on July 9, 2015, the shareholders of the company ratified the appointment of EKS&H LLLP as the company's independent registered public accounting firm for the company's fiscal year ending December 31, 2015.

GlobeImmune to Lay Off Majority of its Workforce

GlobeImmune Inc. announced on June 10, 2015 that it would lay off the majority of its workforce and review its strategic options, sending its stock down by more than 25%.

Similar Private Companies By Industry

Company Name Region
IES Diagnostics Inc. United States
PluroGen Therapeutics, Inc. United States
Delpor, Inc. United States
Renaissance Biomedical Technologies, Inc. United States
Zeis Consulting Group United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GlobeImmune Inc., please visit www.globeimmune.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.